Skip to main content

Research Repository

Advanced Search

Discovery of novel hybrids containing clioquinol−1-benzyl-1,2,3,6-tetrahydropyridine as multi-target-directed ligands (MTDLs) against Alzheimer's disease

Li, Xinnan; Li, Tiantian; Zhang, Pengfei; Li, Xinuo; Lu, Li; Sun, Yuan; Zhang, Bocheng; Allen, Stephanie; White, Lisa; Phillips, James; Zhu, Zheying; Yao, Hequan; Xu, Jinyi

Authors

Xinnan Li

Tiantian Li

Pengfei Zhang

Xinuo Li

Li Lu

Yuan Sun

Bocheng Zhang

Stephanie Allen

James Phillips

ZHEYING ZHU Zheying.Zhu@nottingham.ac.uk
Associate Professor in International Pharmacy and Traditional Medicines

Hequan Yao

Jinyi Xu



Abstract

Based on the multitarget strategy, a series of novel clioquinol−1-benzyl-1,2,3,6-tetrahydropyridine hybrids were identified for the potential treatment of Alzheimer's disease (AD). Biological evaluation in vitro revealed that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE). The optimal compound, 19n, exhibited excellent AChE inhibitory potency (IC50 = 0.11 μM), appropriate metal chelating functions, modulation of AChE- and metal-induced Aβ aggregation, neuroprotection against okadaic acid-induced mitochondrial dysfunction and ROS damage, and interesting properties that reduced p-Tau levels in addition to no toxicity on SH-SY5Y cells observed at a concentration up to 50 μM. Most importantly, compound 19n was more well tolerated (>1200 mg/kg) than donepezil (LD50 = 28.124 mg/kg) in vivo. Moreover, compound 19n demonstrated marked improvements in cognitive and spatial memory in two AD mice models (scopolamine-induced and Aβ1–42-induced) and suppressed inflammation induced by Aβ1–42 in the cortex. The multifunctional profiles of compound 19n demonstrate that it deserves further investigation as a promising lead in the development of innovatively multifunctional drugs for Alzheimer's disease.

Citation

Li, X., Li, T., Zhang, P., Li, X., Lu, L., Sun, Y., …Xu, J. (2022). Discovery of novel hybrids containing clioquinol−1-benzyl-1,2,3,6-tetrahydropyridine as multi-target-directed ligands (MTDLs) against Alzheimer's disease. European Journal of Medicinal Chemistry, 244, Article 114841. https://doi.org/10.1016/j.ejmech.2022.114841

Journal Article Type Article
Acceptance Date Oct 8, 2022
Online Publication Date Oct 12, 2022
Publication Date Dec 15, 2022
Deposit Date Oct 17, 2022
Publicly Available Date Mar 29, 2024
Journal European Journal of Medicinal Chemistry
Print ISSN 0223-5234
Electronic ISSN 1768-3254
Publisher Elsevier BV
Peer Reviewed Peer Reviewed
Volume 244
Article Number 114841
DOI https://doi.org/10.1016/j.ejmech.2022.114841
Keywords Organic Chemistry; Drug Discovery; Pharmacology; General Medicine
Public URL https://nottingham-repository.worktribe.com/output/12599391
Publisher URL https://www.sciencedirect.com/science/article/pii/S0223523422007437?via%3Dihub
Additional Information This article is maintained by: Elsevier; Article Title: Discovery of novel hybrids containing clioquinol−1-benzyl-1,2,3,6-tetrahydropyridine as multi-target-directed ligands (MTDLs) against Alzheimer's disease; Journal Title: European Journal of Medicinal Chemistry; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ejmech.2022.114841; Content Type: article; Copyright: © 2022 Elsevier Masson SAS. All rights reserved.

Files




You might also like



Downloadable Citations